Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2019-04-09 | Jane Wasman, age 62, joined us as a director in April 2019. Ms. Wasman is currently President, International & General Counsel, of Acorda Therapeutics, Inc., a publicly traded biopharmaceutical company. ... The board concluded that Ms. Wasman should continue to serve as a member of the Board in part due to her broad strategic and transactional experience in commercial stage biopharmaceutical companies, as well as her legal and corporate governance background and extensive experience in operational implementation. |
| 2020-04-01 | Jane Wasman, age 63, joined us as a director in March 2019. ... The following three directors are the members of the Corporate Governance, Health Care Compliance Oversight and Nominating Committee: Mr. Lapointe, Dr. Kotzin and Ms. Wasman, who replaced Dr. Ringrose upon his retirement in May of 2019, with Mr. Lapointe serving as Chair. ... The following three directors are the members of the Scientific and Clinical Trial Advisory Committee: Dr. Moos, Dr. Kotzin and Ms. Wasman, who replaced Dr. Ringrose upon his retirement in May of 2019. Dr. Kotzin serves as Chair. ... For services provided in 2019, each non-employee director received, paid on a quarterly basis for quarters served, a yearly retainer of $50,000. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2019: Jane Wasman Fees Earned or Paid in Cash $47,500, Option Awards $5,730, Total $53,230. |
| 2021-04-06 | Jane Wasman, age 64, joined us as a director in March 2019. ... The following three directors are the members of the Corporate Governance, Health Care Compliance Oversight and Nominating Committee: Mr. Lapointe, Dr. Kotzin and Ms. Wasman. ... The following three directors are the members of the Scientific and Clinical Trial Advisory Committee: Dr. Moos, Dr. Kotzin and Ms. Wasman. ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2020: Jane Wasman Fees Earned or Paid in Cash $70,000, Option Awards $62,695, Total $132,695. |
| 2022-04-05 | Jane Wasman, age 65, joined us as a director in March 2019. Ms. Wasman is strategic leader with approximately 25 years of experience in the biopharma industry ... Ms. Wasman is chair of the board of Sellas Life Sciences Group, Inc., a public oncology-focused biotech company, as well as chair of its nominations & governance committee. She is also a member of the board of directors and chair of the nominations, governance and compliance committee of Athersys, Inc. ... Ms. Wasman was selected to serve as a member of the Board in part due to her broad strategic and transactional experience in commercial stage biopharmaceutical companies, as well as her legal and corporate governance background and extensive experience in operational implementation. |
Data sourced from SEC filings. Last updated: 2026-03-05